Serum therapy revisited: animal models of infection and development of passive antibody therapy.
作者信息
Casadevall A, Scharff M D
机构信息
Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461.
出版信息
Antimicrob Agents Chemother. 1994 Aug;38(8):1695-702. doi: 10.1128/AAC.38.8.1695.
Abstract
摘要
相似文献
1
Serum therapy revisited: animal models of infection and development of passive antibody therapy.血清疗法再探讨：感染的动物模型与被动抗体疗法的发展
Antimicrob Agents Chemother. 1994 Aug;38(8):1695-702. doi: 10.1128/AAC.38.8.1695.
2
[Intralumbar Solu-Dacortin treatment of severe pneumococcal meningitis].[腰椎内注射氢化可的松治疗重症肺炎球菌性脑膜炎]
Wien Klin Wochenschr. 1961 Apr 14;73:267-8.
3
4
[Serotherapy of cerebrospinal meningitis].[脑脊液性脑膜炎的血清疗法]
Arch Belg Med Soc. 1973 Jun-Jul;31(6):424-8.
5
Aureomycin in the treatment of meningococcal infection.金霉素治疗脑膜炎球菌感染
Am Pract Dig Treat. 1953 Jan;4(1):12-6.
6
[Preventive and therapeutic action of sera to the Re mutant of Salmonella minnesota in experimental generalized meningococcal infection].
Zh Mikrobiol Epidemiol Immunobiol. 1988 Apr(4):58-62.
7
Symptomatic Primary Selective Immunoglobulin M Deficiency with Nonprotective Pneumococcal Titers Responsive to Subcutaneous Immunoglobulin Treatment.有症状的原发性选择性免疫球蛋白M缺乏症，伴有对皮下免疫球蛋白治疗有反应的非保护性肺炎球菌滴度
Int Arch Allergy Immunol. 2016;170(2):138-40. doi: 10.1159/000447693. Epub 2016 Aug 10.
8
Meningococcal disease; a review.脑膜炎球菌病综述
J Lancet. 1953 Aug;73(8):305-12.
9
Community-acquired acute bacterial meningitis in adults: a clinical update.成人社区获得性急性细菌性脑膜炎：临床更新。
Br Med Bull. 2019 Sep 19;131(1):57-70. doi: 10.1093/bmb/ldz023.
10
[Meningococcal and pneumococcal meningitis treated at the Clinic for Infectious Diseases of Sarajevo].
Med Arh. 1955 Mar-Apr;9(2):15-39.
引用本文的文献
1
A Concise Review of Major Challenges in the Vaccination, Diagnosis and Treatment of Novel Coronavirus Disease 2019.2019年新型冠状病毒病疫苗接种、诊断与治疗中的主要挑战简明综述
Arch Razi Inst. 2024 Dec 31;79(6):1155-1164. doi: 10.32592/ARI.2024.79.6.1155. eCollection 2024 Dec.
2
Models for Inducing Experimental Cryptococcosis in Mice.诱导小鼠实验性隐球菌病的模型。
Methods Mol Biol. 2024;2775:29-46. doi: 10.1007/978-1-0716-3722-7_3.
3
COVID-19: Variants, Immunity, and Therapeutics for Non-Hospitalized Patients.COVID-19：非住院患者的变体、免疫与治疗方法
Biomedicines. 2023 Jul 21;11(7):2055. doi: 10.3390/biomedicines11072055.
4
Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy.拓展单克隆抗体的应用范围：免疫治疗中合成核酸递送的综述
Antibodies (Basel). 2023 Jul 6;12(3):46. doi: 10.3390/antib12030046.
5
Convalescent Plasma in COVID-19.新冠病毒感染康复期血浆治疗
HCA Healthc J Med. 2020 Jun 27;1(3):139-146. doi: 10.36518/2689-0216.1097. eCollection 2020.
6
Development of an anti- therapeutic monoclonal antibody WVDC-5244.抗治疗性单克隆抗体 WVDC-5244 的研发。
Front Cell Infect Microbiol. 2023 Apr 14;13:1117844. doi: 10.3389/fcimb.2023.1117844. eCollection 2023.
7
A systematic review and meta-analysis of the seroconversion rates and adverse effects of COVID-19 mRNA vaccine and COVID-19 viral vector vaccine in kidney transplant recipient patients.一项关于 COVID-19 mRNA 疫苗和 COVID-19 病毒载体疫苗在肾移植受者中的血清转化率和不良反应的系统评价和荟萃分析。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2196893. doi: 10.1080/21645515.2023.2196893. Epub 2023 Apr 14.
8
IgY antibodies: The promising potential to overcome antibiotic resistance.IgY 抗体：克服抗生素耐药性的有前途的潜力。
Front Immunol. 2023 Jan 20;14:1065353. doi: 10.3389/fimmu.2023.1065353. eCollection 2023.
9
The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case-control study.高中和抗体滴度恢复期血浆治疗早期重症 COVID-19 患者的临床结局：一项病例对照研究。
Ann Clin Microbiol Antimicrob. 2022 Nov 19;21(1):51. doi: 10.1186/s12941-022-00542-2.
10
Antibody-Based Immunotherapies as a Tool for Tackling Multidrug-Resistant Bacterial Infections.基于抗体的免疫疗法作为应对多重耐药细菌感染的工具
Vaccines (Basel). 2022 Oct 25;10(11):1789. doi: 10.3390/vaccines10111789.
本文引用的文献
1
A STATISTICAL REVIEW OF 525 CASES OF LOBAR PNEUMONIA.525例大叶性肺炎的统计回顾
Can Med Assoc J. 1931 Dec;25(6):704-6.
2
EXPERIMENTAL MENINGOCOCCAL INFECTION IN MICE.小鼠实验性脑膜炎球菌感染
Science. 1933 Oct 13;78(2024):340-1. doi: 10.1126/science.78.2024.340.
3
TYPE SPECIFIC ANTIPNEUMOCOCCUS RABBIT SERUM.特异性抗肺炎球菌兔血清
Science. 1936 Dec 25;84(2191):579-81. doi: 10.1126/science.84.2191.579.
4
IMMUNIZATION OF HUMAN SUBJECTS WITH THE SPECIFIC CARBOHYDRATES OF TYPE III AND THE RELATED TYPE VIII PNEUMOCOCCUS.用III型及相关VIII型肺炎球菌的特定碳水化合物对人体进行免疫接种。
J Clin Invest. 1935 Nov;14(6):829-32. doi: 10.1172/JCI100731.
5
THE MENINGOCOCCUS (NEISSERIA INTRACELLULARIS).脑膜炎球菌（细胞内奈瑟菌）。
Bacteriol Rev. 1940 Jun;4(2):59-96. doi: 10.1128/br.4.2.59-96.1940.
6
Serological relationships among meningococci.脑膜炎球菌之间的血清学关系。
Bacteriol Rev. 1953 Sep;17(3):175-88. doi: 10.1128/br.17.3.175-188.1953.
7
Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy.接受单克隆抗体治疗患者的人抗鼠免疫球蛋白反应。
Cancer Res. 1985 Feb;45(2):879-85.
8
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.人源化小鼠单克隆抗体在人体内的动力学及免疫反应
Proc Natl Acad Sci U S A. 1989 Jun;86(11):4220-4. doi: 10.1073/pnas.86.11.4220.
9
In vitro antibodies: strategies for production and application.体外抗体：生产与应用策略
Annu Rev Immunol. 1992;10:239-65. doi: 10.1146/annurev.iy.10.040192.001323.
10
Continuous cultures of fused cells secreting antibody of predefined specificity.分泌预定义特异性抗体的融合细胞的连续培养物。
Nature. 1975 Aug 7;256(5517):495-7. doi: 10.1038/256495a0.
Zotero 插件